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Summary
 
Interleukin 5 (IL-5) is the key cytokine involved in regulating the production and many of the
specialized functions of mature eosinophils including priming, adhesion, and survival. We have
generated a point mutant of human IL-5, IL-5 (E12K), which is devoid of agonist activity in
both a TF-1 cell proliferation assay and a human eosinophil adhesion assay. However, IL-5
(E12K) is a potent and specific antagonist of both these IL-5–dependent functional responses.
In both receptor binding and cross-linking studies the wild-type and IL-5 (E12K) mutant ex-
hibit virtually identical properties. This mutant protein was unable to stimulate tyrosine phos-
phorylation in human eosinophils, and blocked the phosphorylation stimulated by IL-5. In
contrast, IL-5 (E12K) is a full agonist in a human eosinophil survival assay, although with re-
duced potency compared to the wild-type protein. This IL-5 mutant enables us to clearly dis-
tinguish between two IL-5–dependent functional responses and reveals distinct mechanisms of
receptor/cellular activation.
 
I
 
L-5 is a cytokine secreted predominantly by T cells, but
also by mast cells and eosinophils (1–3), that has multiple
effects on cells of the eosinophil and basophil lineage. IL-5
induces the differentiation and expansion of eosinophil
precursors in the bone marrow (4) and plays a key role in
regulating many of the specialized functions of mature, ter-
minally differentiated eosinophils, including adhesion (5),
priming of both degranulation and chemotaxis (6, 7), and
the promotion of cell survival (8).
While eosinophils appear to play a protective role during
the host defense response to parasitic infection, accumulat-
ing clinical and experimental evidence has also implicated
the eosinophil in the pathophysiology of a number of aller-
gic diseases such as bronchial asthma, allergic rhinitis, and
atopic dermatitis (9–11). Administration of neutralizing anti–
IL-5 monoclonal antibodies in mouse, guinea pig, or pri-
mate models of allergic asthma inhibits the development of
airway eosinophilia and bronchial hyperreactivity (12–16).
This highlights the eosinophil, and more specifically IL-5,
as an attractive target for therapeutic intervention in allergic
diseases such as asthma.
The effects of IL-5 are mediated through a heterodi-
meric receptor complex composed of a specific ligand bind-
ing 
 
a
 
 subunit and a 
 
b
 
 subunit that is shared by the specific
receptor 
 
a
 
 chains for IL-3 and GM-CSF (17). Although
this common 
 
b
 
 chain (
 
b
 
c
 
) alone has no inherent ligand
binding capacity, it confers high-affinity ligand binding to
the receptor 
 
a/b
 
 chain complex. This phenomenon of in-
creased binding affinity in the presence of the 
 
b
 
c
 
 chain has
been termed affinity conversion, and is most profound for
IL-3 (1,000-fold), with smaller effects on GM-CSF binding
(20–100-fold) and IL-5 binding (2–4-fold) (18–20). The
roles of the respective 
 
a
 
 and 
 
b
 
c
 
 chains in signal transduc-
tion are unclear. Analysis of chimeric receptors composed
of the extracellular domain of the IL-5 receptor 
 
a
 
 chain
and the intracellular domain of the 
 
b
 
c
 
 chain suggests that
ligand-induced dimerization of the cytoplasmic domains of
 
b
 
c 
 
may be sufficient for receptor activation and the trans-
duction of a proliferative signal (21).
 
 
 
In contrast, deletion
and mutational analysis has defined specific regions within
the cytoplasmic domains of both the IL-5 receptor 
 
a
 
 and
 
b
 
c
 
 chains that are essential for the coupling of IL-5 recep-
tors to a proliferative signal (21–24). Thus, although 
 
b
 
c
 
 is
indispensable for the signals leading to proliferation, it is
possible that the receptor 
 
a
 
 chain may contribute to cyto-
kine signal transduction either directly, or by promoting
receptor oligomerization. Furthermore, the relative contri-
butions of the two receptor chains to signal transduction
leading to functional responses other than proliferation are
uncharacterized. Although the precise molecular mecha-
nisms by which the active IL-5 receptor complex directs
these diverse cellular responses in the eosinophil are also
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poorly understood, one of the earliest measurable signaling
events is the phosphorylation of a variety of cellular pro-
teins on tyrosine residues (25).
IL-5 is a disulphide-linked homodimeric glycoprotein with
115 amino acids in each chain (26). Elucidation of the IL-5
crystal structure revealed a novel two domain structure in
which each domain adopts a four 
 
a
 
-helix bundle structure
similar to the cytokine fold in IL-2, IL-4, growth hor-
mone, and GM-CSF (27). Among these related structures,
IL-5 is unique in that each bundle is composed of three he-
lices from one monomer and a fourth helix which is con-
tributed by the second monomer. Recently, the receptor
binding sites on IL-5 have been defined by site-directed
mutagenesis. Residues E88, R90, and E109, within the
carboxy terminus of IL-5, define the IL-5 receptor 
 
a
 
 chain
binding site (28, 29). In addition, the IL-5 mutant E12A,
IL-5 (E12A), exhibits partial agonist activity in a TF-1 cell
proliferation assay, suggesting that the highly conserved E12
in the amino-terminal helix defines a point of contact with
the receptor 
 
b
 
c
 
 chain which is important for 
 
b
 
c
 
 chain acti-
vation and subsequent signal transduction (28). Further-
more, in a TF-1 proliferation assay the IL-5 mutant E13Q
(Due to a single amino acid difference at the amino termi-
nus, IL-5 [E12] as described here is equivalent to IL-5 [E13]
as described by Tavernier [29].), IL-5 (E13Q), was com-
pletely inactive and exhibited antagonist properties (29).
In this study we have produced an IL-5 mutant contain-
ing a charge reversal at position 12, IL-5 (E12K). It has
been characterized in a variety of functional and receptor
binding assays, and we have used this protein as a tool to
reveal distinct mechanisms of receptor/cellular activation in
human eosinophils.
 
Materials and Methods
 
Reagents.
 
Recombinant IL-3, TNF-
 
a
 
, and GM-CSF were
obtained from R&D systems (Abingdon, UK). BS
 
3 
 
(bis[sulfosuc-
cinimidyl] suberate)
 
1
 
 cross-linking reagent was from Pierce and
Warriner (Chester, UK). Na
 
125
 
I for protein iodination, and
 
 125
 
I-
labeled interleukin  5 (
 
125
 
I-IL-5) were obtained from Amersham
International (Amersham, Buckinghamshire, UK). Anti-phospho-
tyrosine antibody (4G10) was obtained from TCS Biologicals
(Buckingham, UK). All other chemicals were obtained from
Sigma (Poole, Dorset, UK).
 
Site-directed Mutagenesis and Protein Expression.
 
Recombinant
human IL-5 was expressed in 
 
E. coli
 
 and purified to homogeneity
as previously described (30). IL-5 (E12K) was generated by site-
directed mutagenesis, expressed in 
 
E. coli
 
 and purified as previ-
ously described (28) with the following modifications. Renatur-
ation was carried out by dropwise dilution of the protein in 6 M
urea, into 0.1 M ethanolamine, pH 9.8, containing 2.5 M urea,
10% ammonium sulphate, 1 mM reduced glutathione, and 0.1 mM
oxidized glutathione to a final protein concentration of 10 
 
m
 
g/ml,
and stirred overnight at 4
 
8
 
C. The solution was dialyzed against
three changes of 0.1 M ethanolamine, and concentrated 10-fold
by ultrafiltration before gel filtration. Circular dichroism spectral
analysis confirmed that the secondary and tertiary structure was
identical to wild-type IL-5 (data not shown).
 
Receptor Binding Assays.
 
In competition binding studies IL-5
and IL-5 (E12K) were assayed for their relative ability to bind to re-
combinant IL-5 receptor 
 
a
 
 chain alone, or the receptor 
 
a/b
 
 chain
complex as expressed on TF-1 cells, as previously described (31).
In brief, for low-affinity binding studies the extracellular do-
main of the IL-5 receptor 
 
a
 
 chain, fused with the IgG binding
domain of protein A (IL-5R
 
a
 
-ZZ), was incubated with rabbit IgG
and anti-rabbit–coated fluoromicrosphere beads (Amersham Inter-
national, UK) for 2 h at 4
 
8
 
C. The resultant complex was incu-
bated with 100 pM 
 
125
 
I-IL-5 in the presence of increasing con-
centrations of unlabeled cytokines as indicated. After incubation for
4 h at room temperature, bound radioligand was measured in a
Wallac 1450 Microbeta scintillation counter set up in scintillation
proximity assay (SPA) mode. Nonspecific binding was measured
in the presence of a 500-fold molar excess of unlabeled IL-5.
For cell-based binding studies TF-1 cells (1
 
 3 
 
10
 
6
 
) were incu-
bated with 200 pM 
 
125
 
I-IL-5 for 2 h at room temperature in the
presence of increasing concentrations of unlabeled cytokines as in-
dicated. After separation of bound and free ligand by centrifuga-
tion through oil (16% paraffin oil, 84% silicone oil; BDH, Dorset,
UK) the cell-associated radioligand was quantified in a gamma
counter. Nonspecific binding was measured in the presence of a
300-fold molar excess of unlabeled IL-5.
 
TF-1 Cell Proliferation Assay.
 
Cytokine-induced
 
 
 
proliferation of
the human erythroleukemia cell line TF-1 was measured as previ-
ously described (28). In brief, assays were performed in 96-well mi-
crotiter plates containing 5
 
 3 
 
10
 
3 
 
cells/well with the indicated
cytokines. After incubation for 60–72 h at 37
 
8
 
C the induction of
proliferation was measured using the Cell Titer 96
 
Ô
 
 nonradioactive
cell proliferation assay (Promega, Southampton, UK), according
to the manufacturer’s instructions.
 
Eosinophil Purification.
 
Human peripheral blood eosinophils
were isolated from healthy donors with mildly elevated eosino-
phil count, by a CD16-negative selection protocol as previously
described (32).
 
 
 
Eosinophil purity was always 
 
.
 
95%.
 
Eosinophil Activation Assay.
 
Cytokine-induced activation of puri-
fied eosinophils, as measured by adhesion to immobilized IgG, was
assayed as previously described (32). In brief, 5
 
 3 
 
10
 
3 
 
 eosinophils
were incubated with the indicated cytokines for 30 min at 37
 
8
 
C,
in a 96-well microtiter plate precoated with human IgG. After a
washing step, the adherent eosinophils were lysed and the endog-
enous peroxidase activity measured in a colorimetric assay using
 
o
 
-phenylenediamine as a substrate.
 
Eosinophil Survival Assay.
 
Purified eosinophils were suspended at
10
 
6 
 
cells/ml in DMEM containing 10% FCS, 50 U/ml penicillin,
and 50 
 
m
 
g/ml streptomycin (GIBCO, Paisley, Scotland) in mi-
crotiter plates, in the presence or absence of wild-type IL-5 or IL-5
(E12K). After incubation at 37
 
8
 
C for 72 h, cell viability was as-
sessed by trypan blue exclusion, counting a minimum of 200
cells. For antibody blocking experiments, human eosinophils
were incubated with the indicated concentrations of cytokines in
the presence or absence of 250 
 
m
 
g/ml anti–IL-5 neutralizing anti-
body, TRFK-5 (33). For polymyxin B experiments agonists were
preincubated with 500 U/ml polymyxin B for 1 h at 37
 
8
 
C before
addition of purified human eosinophils.
 
Cross-linking of Radiolabeled IL-5 or IL-5 (E12K) to IL-5 Receptor
 
a
 
 and 
 
b
 
 Chains Expressed on COS Cells.
 
For cross-linking stud-
ies recombinant human IL-5 and IL-5 (E12K) were iodinated by
 
1
 
Abbreviations used in this paper:
 
 BS
 
3
 
, bis(sulfosuccinimidyl) suberate; ED
 
80
 
,
concentration required to give 80% of the maximum biological response;
IL-5R-zz, extracellular domain of the IL-5 receptor 
 
a
 
 chain, fused with the
IgG binding domain of protein A; MOPS, 3-[
 
N
 
-morpholino] propane-
sulfonic acid; SPA, scintillation proximity assay. 
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a modified chloramine-T method essentially as described previ-
ously (28).
COS cells were plated at 10% confluence in 175-cm
 
2
 
 flasks and
grown overnight in DMEM containing 10% FCS, 50 U/ml peni-
cillin, and 50 
 
m
 
g/ml streptomycin. Cells were then transiently trans-
fected with human IL-5 receptor 
 
a
 
 and 
 
b
 
c
 
 chain expression plas-
mids (10 
 
m
 
g each) by a calcium phosphate precipitation method,
using the Mammalian Transfection Kit (Stratagene, Cambridge,
UK), according to the manufacturers instructions. Cells were har-
vested 48 h after transfection in PBS containing 5 mM EDTA and
counted.
Transfected cells (5
 
 3 
 
10
 
5
 
) were incubated for 2 h at 4
 
8
 
C in
200 
 
m
 
l binding medium (RPMI 1640 containing 0.5% wt/vol
bovine serum albumin and 20 mM Hepes, pH 7.4) with 70 nM
 
125
 
I-IL-5 or 
 
125
 
I-IL-5 (E12K)
 
 
 
in the presence or absence of a 100-
fold molar excess of unlabeled IL-5. Cells were then washed
twice, resuspended in 1 ml of ice-cold
 
 
 
PBS, and 50 mM BS
 
3
 
cross-linker was added to a final concentration of 1 mM. After in-
cubation for 30 min at 4
 
8
 
C, cells were washed twice in PBS and
resuspended in 150 
 
m
 
l lysis buffer (50 mM Hepes pH 7.4, con-
taining 2 mM EDTA, 2 mM EGTA, 1 mM 4-[2-aminoethyl]
benzenesulfonyl fluoride, 5 
 
m
 
g/ml leupeptin, 5 
 
m
 
g/ml pepstatin,
5 
 
m
 
g/ml antipain, and 1% vol/vol Triton X-100). The cell lysate
was incubated for 10 min on ice, centrifuged for 10 min at
12,000 rpm in a microfuge, and the supernatant mixed with 4
 
3
 
SDS sample buffer containing 10% 2-ME. Extracts were analyzed
on a 4–12% NuPAGE SDS–polyacrylamide gel (Novex, San Di-
ego, CA) run in MOPS buffer (3-[
 
N
 
-Morpholino] propane-
sulfonic acid). After electrophoresis gels were fixed and dried and
the radiolabeled bands visualized using a PhosphoImager (Molec-
ular Dynamics, Buckinghamshire, UK).
Detection of Phosphotyrosine Containing Proteins by Western Blot-
ting. Human eosinophils (5 3 105) were incubated in the pres-
ence of indicated concentrations of cytokines for 5 min at 378C,
in PBS containing 0.4% human serum albumin. The cells were
then pelleted at 48C, resuspended in 13 NuPAGE sample buffer
containing 2.5% 2-ME and 1 mM sodium orthovanadate and
boiled for 5 min. Extracts were analyzed on a 4–12% NuPAGE
SDS–polyacrylamide gel run in MOPS buffer and transferred to
hybond-ECL membrane (Amersham International, Amersham,
UK). Blots were probed with the anti-phosphotyrosine antibody
4G10, and proteins visualized using a horseradish peroxidase-
conjugated goat anti–mouse secondary antibody (Sigma, Poole,
Dorset, UK) with enhanced chemiluminescence (ECL) detection
(Amersham International, UK).
Data Analysis. Receptor binding and biological data were
analyzed using Grafit 3.01 as previously described (28).
Results
Relative Receptor Binding Properties of IL-5 and IL-5 (E12K).
Wild-type human IL-5 and a mutant IL-5 containing a
charge reversal mutation at position 12, IL-5 (E12K), were
expressed in E. coli and purified to homogeneity. As a
means of comparing the receptor binding properties of wild-
type IL-5 and IL-5 (E12K), both proteins were assayed for
their relative ability to bind to the IL-5 receptor a chain
alone, or to the high-affinity a/b receptor complex. In
competition binding experiments, using the recombinant
extracellular domain of the IL-5 receptor a chain in an
SPA assay format, IL-5 (E12K) exhibited a 1.7 6 0.2-fold
(n 5 6)-fold reduction in binding affinity to the receptor a
chain relative to wild-type IL-5 (Fig. 1 A). The interaction
with the high-affinity receptor complex was assessed in a
cell based competition binding assay using TF-1 cells which
express both the IL-5 receptor a and bc chains. In this cell
based system IL-5 (E12K) exhibited a 4.5 6 1.2-fold (n 5 5)
reduction in binding affinity relative to wild-type IL-5
(Fig. 1 B). The shift in relative binding of IL-5 (E12K) and
wild-type IL-5 to the high-affinity a/b complex, compared
Figure 1. Comparative binding of wild-type IL-5 and IL-5 (E12K) to
recombinant IL-5 receptor a chain (A) or to the receptor a/b complex
on TF-1 cells (B). (A) Recombinant IL-5 receptor a-chain, immobilized
on SPA beads, were incubated with 100 pM 125I-IL-5 in the presence of
increasing concentrations of unlabeled wild-type IL-5 (open circles) or IL-5
(E12K) (closed circles). After incubation for 4 h at room temperature sam-
ples were counted in a Wallac 1450 microbeta counter set up in SPA
mode. The results show competition as percentage of maximum binding
(% B/Bo). Each value represents the mean 6 SEM of four independent
experiments for wild-type and six independent experiments for IL-5
(E12K). (B) TF-1 cells were incubated at room temperature for 2 h in the
presence of 200 pM 125I-IL-5 and increasing concentrations of unlabeled
wild-type (open circles) or IL-5 (E12K) (closed circles). After separation of
bound and free ligand the cell-associated radioligand was quantified in a
gamma counter. The results show competition as percentage of maxi-
mum binding (% B/Bo). Each value represents the mean 6 SEM of five
independent experiments.124 Interleukin-5 Mutant Distinguishes Two Functions in Human Eosinophils
to the a chain alone, was found to be statistically nonsignif-
icant (P 5 0.084), as assessed by an analysis of variance
technique.
Chemical Cross-linking of Radiolabeled IL-5 and IL-5 (E12K)
to IL-5 Receptors. To determine whether IL-5 (E12K) is able
to interact with the IL-5 receptor bc chain, we employed
receptor cross-linking studies. The chemical cross-linking
of 125I-IL-5 or 125I-IL-5 (E12K) to COS cells transfected
with IL-5 receptor a and bc chains revealed identical pat-
terns of cross-linked species of z70 and 150 kD under re-
ducing conditions (Fig. 2), which correspond to the pre-
dicted molecular mass of the receptor a and bc subunits,
respectively, bound to a monomer of IL-5. Furthermore,
the appearance of these bands was blocked by addition of a
100-fold molar excess of unlabeled IL-5 during the incuba-
tion, confirming that both 125I-IL-5 and 125I-IL-5 (E12K)
can be specifically cross-linked to both IL-5 receptor a and
bc chains.
Biological Properties of IL-5 (E12K) in a TF-1 Proliferation
Assay. Wild-type IL-5 induced the proliferation of the
human erythroleukemia cell line TF-1 in a concentration-
dependent fashion  (ED50 5 2.6 6 0.6 pM, n 5 4), while
IL-5 (E12K) was unable to stimulate proliferation even at
concentrations up to 400 nM, a concentration 160,000-
fold higher than the concentrations of wild-type IL-5 re-
quired to elicit half maximal proliferation of TF-1 cells
(Fig. 3 A).
Having determined that IL-5 (E12K) was able to bind to
IL-5 receptors with almost wild-type affinity, yet was un-
able to elicit a proliferative response in TF-1 cells, we
tested this mutant for its ability to antagonize the effects of
IL-5 in a TF-1 proliferation assay. As seen in Fig. 3 B, IL-5
(E12K) antagonized the effect of IL-5 in a concentration-
dependent manner. Proliferation of TF-1 cells, in the pres-
ence of 77 pM wild-type IL-5, was totally inhibited by
100 nM IL-5 (E12K) and 50% inhibition was achieved at
10.3 6 2.8 nM (n 5 6), which represents a 130-fold molar
excess of IL-5 (E12K) over wild-type. Furthermore, in the
same functional assay IL-5 (E12K) did not significantly in-
hibit TF-1 proliferation stimulated by IL-3 or GM-CSF
(Fig. 3 B). This demonstrates not only that IL-5 (E12K) is a
Figure 2. Chemical cross-linking of wild-type IL-5 and IL-5 (E12K) to
IL-5 receptors. COS cells transfected with human IL-5 receptor a and bc
chain cDNAs were incubated with z70 nM 125I-IL-5 or 125I-IL-5 (E12K)
for 2 h at 48C in the presence or absence of a 100-fold molar excess of
unlabeled IL-5, then cross-linked with 1 mM BS3. After detergent lysis of
cells, soluble extracts were analyzed by SDS-PAGE and radiolabeled
bands visualized by a PhosphoImager.
Figure 3. IL-5 (E12K) exhibits no agonist activity (A) and is a specific
IL-5 antagonist (B) in a TF-1 cell proliferation assay. (A) TF-1 cells were
incubated with increasing concentrations of either wild-type (open circles)
or IL-5 (E12K) (closed circles) for 60–72 h and the induction of prolifera-
tion was measured using a nonradioactive cell proliferation assay. Each
value represents the mean 6 SEM of four independent experiments. (B)
TF-1 cell proliferation was assayed at either 77 pM IL-5 (open circles), 133
pM IL-3 (closed squares) or 14 pM GM-CSF (closed triangles) in the pres-
ence of increasing concentrations of IL-5 (E12K). The concentrations of
wild-type cytokines represent zED80’s (concentration of cytokine re-
quired to give 80% of the maximum biological response) for proliferation
in our TF-1 cell line. Each value represents the mean 6 SEM of six inde-
pendent experiments. 100% values for IL-5–, IL-3–, and GM-CSF–induced
proliferation were equivalent to A550 of 0.68 6 0.02, 0.73 6 0.18, and
0.64 6 0.04, respectively. Unstimulated levels were 0.03 6 0.02.125 McKinnon et al.
specific IL-5 receptor antagonist, but also excludes the pos-
sibility of IL-5 (E12K)–dependent cellular toxicity.
Biological Properties of IL-5 (E12K) in an Eosinophil Activa-
tion Assay. To confirm and extend our observations to
additional IL-5–induced cellular responses, we switched
our studies to human peripheral blood eosinophils, a termi-
nally differentiated cell type in which IL-5 stimulates multi-
ple functional responses. We have established a sensitive and
reliable in vitro assay for analysis of cytokine-induced eosin-
ophil activation based on adhesion to immobilized IgG. In
this assay, wild-type IL-5 induced a concentration-depen-
dent increase in eosinophil adhesion to IgG (ED50 5 1.3 6
0.1 pM, n 5 3), while the mutant E12K was incapable of
inducing eosinophil adhesion even up to concentrations of
1 mM, a concentration 400,000-fold higher than the ED50
for wild-type IL-5 (Fig. 4 A). In the same functional assay
IL-5 (E12K) completely antagonized the effects of IL-5 in a
concentration-dependent fashion. Eosinophil adhesion in the
presence of 20 pM wild-type IL-5 was completely inhib-
ited by 50 nM IL-5 (E12K) with 50% inhibition achieved
at 1.9 6 0.1 nM (n 5 3), which represents a 95-fold molar
excess of IL-5 (E12K) over wild-type (Fig. 4 B). In addi-
tion, the inhibitory effect of IL-5 (E12K) was specific for
IL-5 induced adhesion with no significant inhibition of IL-3,
GM-CSF, or TNF-a across the range of IL-5 (E12K) con-
centrations found to inhibit IL-5 (Fig. 4 B).
Biological Properties of IL-5 (E12K) in an Eosinophil Survival
Assay. Mature eosinophils that have been separated from
peripheral blood do not survive more than 4 d in vitro
without the addition of cytokines. The eosinophilopoietic
cytokines IL-5, IL-3, and GM-CSF have all been reported
to promote eosinophil survival, and so maintain cell viabil-
ity (8, 34, 35). We therefore assessed the relative ability of
wild-type IL-5 and IL-5 (E12K) to promote eosinophil sur-
vival. Purified human peripheral blood eosinophils were
incubated in the presence of increasing concentrations of
wild-type IL-5 or IL-5 (E12K) and eosinophil viability
measured by trypan blue exclusion, after a period of 72 h.
Both IL-5 and IL-5 (E12K) were able to promote eosino-
phil survival in a concentration-dependent manner with
ED50 values of 0.4 6 0.1 pM and 20.6 6 8.7 nM, respec-
tively (n 5 5) (Fig. 5 A). Although IL-5 (E12K) promoted
eosinophil survival with a 50,000-fold reduction in biolog-
ical potency with respect to wild-type IL-5, it was still a
full agonist capable of eliciting a maximal biological re-
sponse not significantly different from wild-type IL-5.
One trivial explanation for the agonist activity of IL-5
(E12K) in the eosinophil survival assay is the contamination
of this E. coli expressed cytokine with bacterial LPS, which
has been reported to promote eosinophil survival through
the autocrine production of GM-CSF (36). To exclude this
possibility a series of control experiments were performed
(Fig. 5 B). First, the agonist activity of IL-5 (E12K) was
completely abolished after boiling for 15 min. Further-
more, pretreatment with polymyxin B, an LPS inhibitor
(36), blocked LPS- but not IL-5 or IL-5 (E12K)–induced
eosinophil survival. In addition, the anti–IL-5 neutralizing
antibody TRFK-5 blocked the agonist activity of IL-5 (E12K)
and wild-type IL-5, but not IL-3, GM-CSF or LPS in the
eosinophil survival assay (Fig. 5 B). This confirms that the
eosinophil survival activity is specifically mediated via IL-5
(E12K) and excludes the possibility of an LPS-dependent
mechanism.
Figure 4. IL-5 (E12K) exhibits no agonist activity (A) and is a specific
IL-5 antagonist (B) in a cytokine induced eosinophil activation assay. (A)
Human eosinophils were incubated with increasing concentrations of ei-
ther wild-type (open circles) or IL-5 (E12K) (closed circles) for 30 min at
378C, in a 96-well microtiter plate precoated with human IgG. After a
washing step, the adherent eosinophils were lysed and the endogenous
peroxidase activity measured in a colorimetric assay. (B) In antagonist ex-
periments eosinophils were incubated with either 20 pM IL-5 (open cir-
cles), 180 pM IL-3 (closed squares), 6 pM GM-CSF (closed triangles), or
1,000 pM TNF-a (inverted triangles) in the presence of increasing concen-
trations of IL-5 (E12K). The concentrations of wild-type cytokines repre-
sent zED80’s in the eosinophil adhesion assay. In both panels each value
represents the mean 6 SEM of three independent experiments using dif-
ferent blood donors. 100% values for IL-5–, IL-3–, GM-CSF–, and
TNF-a–induced adhesion were 0.56 6 0.07, 0.76 6 0.05, 0.41 6 0.07,
and 0.49 6 0.06, respectively. Unstimulated levels were 0.15 6 0.05.126 Interleukin-5 Mutant Distinguishes Two Functions in Human Eosinophils
Relative Effects of IL-5 and IL-5 (E12K) on Tyrosine Phos-
phorylation in Eosinophils. Stimulation of eosinophils with
IL-5 induced an increase in the phosphotyrosine content of
a number of proteins, in a concentration-dependent man-
ner, with the predominant phosphorylated species at 150-kD
(Fig. 6). In contrast to wild-type IL-5, IL-5 (E12K) did not
stimulate tyrosine phosphorylation even at concentrations up
to 5 mM. Furthermore, 500 nM IL-5 (E12K) completely
inhibited the tyrosine phosphorylation of this 150-kD pro-
tein stimulated by 250 pM IL-5 (Fig. 6).
Discussion
In a systematic program of alanine scanning mutagenesis
we previously demonstrated that IL-5 (E12A) exhibited
partial agonist activity in a TF-1 cell proliferation assay and
proposed that E12 defined a contact point for the IL-5 re-
ceptor b chain. We based this conclusion not only on bio-
logical activity but on the reduction in affinity of E12A for
the IL-5 receptor a/b chain compared to the a chain alone
(28). Generating a charge reversal at this putative bc chain
binding site residue, IL-5 (E12K), has allowed us to further
investigate the effect of this mutation.
Glutamic acid-12 resides on the amino-terminal helix of
IL-5 at an analogous position to E21 in GM-CSF and E22
in IL-3. Charge reversal mutations at these positions in IL-3
and GM-CSF resulted in proteins which were unaltered in
binding their respective a chains, but demonstrated a re-
duction in high-affinity binding (37, 38). For IL-5 (E12K)
we also see essentially wild-type binding to the IL-5 recep-
tor a chain, but a reduction in high affinity binding of
z2.6-fold. Although this result is entirely consistent with
the reduction in high affinity we previously observed with
IL-5 (E12A) (28), the apparent reduction in the affinity of
IL-5 (E12K) for the a/b complex is not statistically signifi-
cant (P 5 0.084). Since the affinity conversion conferred
by bc on the IL-5/IL-5 receptor–a chain complex is small
(two- to fourfold), compared to the much larger shifts in
affinity seen with both GM-CSF and IL-3, this lack of sta-
tistical significance is probably due to the difficulty of mea-
suring such small changes. The contribution of the bc chain
to IL-5 (E12K) high-affinity binding is difficult to measure
clearly through competition binding studies. However we
demonstrated by chemical cross-linking studies that, as with
wild-type IL-5, IL-5 (E12K) is still capable of contacting
not only the receptor a chain but also the bc chain. This
result is consistent with the pattern of cross-linking ob-
tained with IL-5 (E13Q), which has a similar antagonist bi-
ological profile in TF-1 cells (29). Such cross-linking ex-
periments have not been published with human GM-CSF
(E22R) or IL-3 (E21R) and it is not clear whether these
mutants can similarly cross-link to the bc chain in the ab-
sence of high affinity binding. However, a biologically ac-
tive murine GM-CSF mutant (E21A) has been described
which binds the a/b complex with low affinity only, yet is
able to cross-link to both the a and bc chains of the recep-
tor (39). As suggested by Tavernier et al. (29), this may in-
dicate that affinity conversion and receptor activation can
be uncoupled.
In contrast to IL-5 (E12A), the IL-5 (E12K) mutant was
completely devoid of agonist activity in a TF-1 cell prolif-
eration assay and was a full and selective antagonist of IL-5
in this functional assay. While IL-3 (E21R) retains agonist
activity for TF-1 proliferation at 20,000-fold reduced po-
tency relative to wild-type IL-3 (37), GM-CSF (E22R)
lacks agonist activity and is a specific GM-CSF antagonist
Figure 5. Both wild-type IL-5 and IL-5 (E12K) promote eosinophil
survival (A). The agonist activity of E12K can be abolished by boiling, or
pretreatment with a neutralizing anti–IL-5 antibody but not by poly-
myxin B (B). (A) Increasing concentrations of either wild-type (open cir-
cles) or IL-5 (E12K) (closed circles) were incubated with purified human
eosinophils for 72 h at 378C and eosinophil viability measured by trypan
blue exclusion. Data expressed as a percentage of the maximum survival
effect obtained with wild-type IL-5 in each experiment (66% 6 5.6 via-
ble cells, compared to 2.7% 6 1.7 in the absence of cytokine). Each value
represents the mean 6 SEM of six independent experiments using differ-
ent blood donors. (B) Human eosinophils were incubated with either 1 pM
IL-5, 50 nM IL-5 (E12K), 40 pM IL-3, 20 pM GM-CSF, or 1 ng/ml
LPS alone, or in the presence of 250 mg/ml anti–IL-5 neutralizing anti-
body, TRFK-5, or after pretreatment with 500 U/ml polymyxin B for 1 h
at 378C. For boiling experiments, IL-5 (E12K) was boiled for 15 min be-
fore incubation with eosinophils. Eosinophil viability was measured after
72 h by trypan blue exclusion. The concentrations of cytokines represent
zED80’s in the eosinophil survival assay. Data expressed as a percentage of
the maximum survival effect obtained with wild-type IL-5 in each exper-
iment (61% 6 8.0 viable cells, compared to 17% 6 3.7 in the absence of
cytokine). Each value represents the mean 6 SEM of at least three inde-
pendent experiments.127 McKinnon et al.
(40). Furthermore, the antagonistic properties of IL-5 (E12K)
are not restricted to inhibition of IL-5–induced cell prolif-
eration. In human eosinophils IL-5 (E12K) was a selective
antagonist of IL-5 induced eosinophil activation, as assessed
by adhesion to immobilized IgG, exhibiting no effect on
eosinophil activation induced by the related cytokines IL-3
and GM-CSF or the unrelated cytokine TNF-a.
Taken together these mutagenesis studies suggest that the
structural conservation at both the cytokine and receptor
level for IL-5, IL-3, and GM-CSF underlie a common
mechanism of receptor binding and activation, and that the
acidic residues within the amino terminal helix of all three
cytokines form a contact point for the bc chain which con-
tributes to receptor activation and, for the latter two cyto-
kines at least, high-affinity binding. Somewhat surprisingly
however, IL-5 (E12K) was clearly a full agonist in an eosin-
ophil survival assay, albeit with a 50,000-fold reduction in
potency relative to wild-type IL-5. This survival effect of
IL-5 (E12K) was not due to the presence of contaminating
LPS and was consistently seen in the same eosinophils in
which IL-5 (E12K) antagonized IL-5–induced adhesion to
IgG. Clearly this single point mutation in IL-5 is able to
distinguish between two IL-5–dependent functional re-
sponses in the same cell type. This apparent functional di-
chotomy in the actions of IL-5 (E12K) implies that different
functional responses within the same cell, activation versus
survival, are mediated through distinct mechanisms of cel-
lular activation.
In the context of IL-5, E12 appears to be necessary for
activating the IL-5 receptor bc leading to an eosinophil ac-
tivation signal. However, the fact that IL-5 (E12K) pro-
motes eosinophil survival suggests that residues on IL-5
other than E12 are involved in receptor activation leading
to a survival signal. The reduction in potency of IL-5
(E12K) with respect to wild-type IL-5 further suggests that,
although not required for full agonist activity, E12 must
contribute to the efficiency of receptor activation. This
would indicate that multiple points of contact between IL-5
and its receptor complex are required for complete recep-
tor activation. Since IL-5 (E12K) can be cross-linked to the
receptor bc, residues other than E12 may directly contact
bc contributing to its complete activation. Such a model
may also account for the ability of human IL-3 (E22R) and
murine GM-CSF (E21A) to exhibit biological activity de-
spite the lack of high-affinity binding (37,39). However, a
direct role for the IL-5 receptor a chain in signal transduc-
tion has been inferred from both deletion and point muta-
tion studies in the intracellular domain of the a chain, re-
sulting in the loss of IL-5–induced cell proliferation (21,
22). Furthermore, it has been proposed that the ligand-spe-
cific a subunits of the IL-5, IL-3, and GM-CSF receptors
may mediate cytokine-specific signals leading to different
cellular responses (41). Since mutations at E12 appear to be
unaffected in a-chain binding, it is also possible that ele-
ments of the survival signal emanate from the a chain.
These properties of IL-5 (E12K) highlight its potential
use as a tool for dissecting signaling pathways from the acti-
vated IL-5 receptor complex leading to distinct IL-5–depen-
dent functional responses, in particular eosinophil survival.
Initial experiments in eosinophils measuring one of the ear-
liest detectable signaling events, tyrosine phosphorylation,
highlighted opposing effects of IL-5 and IL-5 (E12K). Wild-
type IL-5, but not IL-5 (E12K), was able to activate ty-
rosine phosphorylation of a major 150-kD protein species
and furthermore, the IL-5–dependent phosphorylation of
this protein was inhibited by IL-5 (E12K).
In summary, we have identified an IL-5 point mutant,
IL-5 (E12K), which lacks agonist activity and is a potent
antagonist in both a TF-1 cell proliferation assay and an
eosinophil activation assay, yet exhibits agonist activity in
promoting eosinophil survival. The dual agonist and antag-
onist properties of IL-5 (E12K) can be explained via dis-
tinct mechanisms of cellular/receptor activation. We are
currently attempting to elucidate the precise mechanism by
which this IL-5 mutant exerts its agonist effect.
Figure 6. Wild-type IL-5 but
not IL-5 (E12K) stimulates ty-
rosine phosphorylation of a 150-
kD protein in human eosino-
phils. Human eosinophils were
stimulated with the indicated
concentrations of cytokines for 5
min at 378C. Cells were pelleted,
resuspended in SDS sample
buffer and lysates were electro-
phoresed and immunoblotted
with anti-phosphotyrosine anti-
body.
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